Prognostic value of anemia in newly diagnosed metastatic prostate cancer: A Multivariate Analysis of Southwest Oncology Group Study 8894

Journal of Urology

Volumn 172, Issue 6 I, 2004, Pages 2213-2217

  Beer, Tomasz M ^a,b   Tangen, Catherine M ^c   Bland, Lisa B ^b   Thompson, Ian M ^d   Crawford, E David ^e  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Southwest Oncology Group   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

Anemia; Prognosis; Prostatic neoplasms

Indexed keywords

HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN;

AGE; ANEMIA; ARTICLE; BONE PAIN; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RACE DIFFERENCE;

EID: 8644225617     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000147771.92104.83     Document Type: Article

References (20)

1. de Voogt, H. J., Suciu, S., Sylvester, R., Pavone-Macaluso, M., Smith, P. H., de Pauw, M. et al: Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials. J Urol, 141: 883, 1989
2. Mulders, P. F., Dijkman, G. A., Fernandez del Moral, P., Theeuwes, A. G. and Debruyne, F. M.: Analysis of prognostic factors in disseminated prostatic cancer. An update. Dutch Southeastern Urological Cooperative Group. Cancer, 65: 2758, 1990
3. Eisenberger, M. A., Crawford, E. D., Wolf, M., Blumenstein, B., McLeod, D. G., Benson, R. et al: Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. Semin Oncol, 21: 613, 1994
4. Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J. et al: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med, 339: 1036, 1998
5. Soloway, M. S., Hardeman, S. W., Hickey, D., Raymond, J., Todd, B., Soloway, S. et al: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer, 61: 195, 1988
6. Ghafar, M. A., Anastasiadis, A. G., Chen, M. W., Burchardt, M., Olsson, L. E., Xie, H. et al: Acute hypoxia increases the aggressive characteristics and survival properties of prostate cancer cells. Prostate, 54: 58, 2003
7. Movsas, B., Chapman, J. D., Hanlon, A. L., Horwitz, E. M., Greenberg, R. E., Stobbe, C. et al: Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology, 60: 634, 2002
8. Frederiksen, L. J., Siemens, D. R., Heaton, J. P., Maxwell, L. R., Adams, M. A. and Graham, C. H.: Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate. J Urol, 170: 1003, 2003
9. Vaupel, P., Mayer, A., Briest, S. and Hockel, M.: Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. Cancer Res, 63: 7634, 2003
10. Vaupel, P., Thews, O., Mayer, A., Hockel, S. and Hockel, M.: Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level? Strahlenther Onkol, 178: 727, 2002
11. Gardner, L. B. and Benz, E. J.: Anemia of chronic diseases. In: Hematology Basic Principles and Practice, 3rd ed. Edited by R. Hoffman, E. J. Benz, S. J. Shattil, B. Furie, H. J. Cohen, L. E. Silberstein et al. Philadelphia: Churchill Livingstone, pp. 383-388, 2000
12. Means, R. T., Jr. and Krantz, S. B.: Progress in understanding the pathogenesis of the anemia of chronic disease. Blood, 80: 1639, 1992
13. Silvestris, F., Tucci, M., Quatraro, C. and Dammacco, F.: Recent advances in understanding the pathogenesis of anemia in multiple myeloma. Int J Hematol, 78: 121, 2003
14. Bogdanos, J., Karamanolakis, D., Tenta, R., Tsintavis, A., Milathianakis, C., Mitsiades, C. et al: Endocrine/paracrine/ autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton. Endocr Relat Cancer, 10: 279, 2003
15. Yang, L., Wang, L., Lin, H. K., Kan, P. Y., Xie, S., Tsai, M. Y. et al: Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem Biophys Res Commun, 305: 462, 2003
16. Lee, S. O., Lou, W., Hou, M., de Miguel, F., Gerber, L. and Gao, A. C.: Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res, 9: 370, 2003
17. Twillie, D. A., Eisenberger, M. A., Carducci, M. A., Hseih, W. S., Kim, W. Y. and Simons, J. W.: Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology, 45: 542, 1995
18. Corcoran, N. M. and Costello, A. J.: Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer? BJU Int, 91: 545, 2003
19. Albrecht, M., Doroszewicz, J., Gillen, S., Gomes, I., Wilhelm, B., Stief, T. et al: Proliferation of prostate cancer cells and activity of neutral endopeptidase is regulated by bombesin and IL-1beta with IL-1beta acting as a modulator of cellular differentiation. Prostate, 58: 82, 2004
20. Lee, L. F., Louie, M. C., Desai, S. J., Yang, J., Chen, H. W., Evans, C. P. et al: Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene, 23: 2197, 2004